Associations of Maternal Fructosamine before Delivery in Gestational Diabetes Mellitus Pregnancies with Neonatal Glucometabolic Disorders

Table 2

The associations between the maternal FMN_ALB before delivery and neonatal glucometabolic disorders.

	(, %)	(, %)	OR (95% CI)		aOR (95% CI)
Neonatal glucometabolic disorders	37/66, 56.06%	76/198, 38.38%	2.05 (1.17-3.60)	0.013	2.50 (1.34-4.65)	0.004
Neonatal hypoglycemia	, 43.94%	, 29.80%	1.85 (1.04-3.28)	0.036	2.18 (1.16-4.10)	0.016
Neonatal glucose intolerance	, 19.70%	, 13.13%	1.62 (0.78-3.38)	0.196	1.76 (0.82-3.79)	0.149
	percentile (, %)	percentile (, %)	OR (95% CI)		aOR (95% CI)
Neonatal glucometabolic disorders	, 70.37%	, 39.66%	3.61 (1.52-8.59)	0.004	5.70 (2.18-14.89)	<0.001
Neonatal hypoglycemia	, 51.85%	, 31.22%	2.37 (1.06-5.30)	0.035	3.72 (1.48-9.31)	0.005
Neonatal glucose intolerance	, 25.93%	, 13.50%	2.24 (0.88-5.73)	0.092	2.21 (0.80-6.12)	0.125

FMN_ALB: the ratio of fructosamine to plasma albumin; OR: odds ratios; aOR: adjusted odds ratios; CI: confidence interval. aOR, adjusted for maternal age (≥35 and <35 years), III degrees or meconium-stained amniotic fluid (yes and no), placenta previa or placental abruption (yes and no), antenatal corticosteroid use (yes and no), neonatal gestational age (<32, 32-33, 34-36, and ≥37weeks), birth weight (<1500, 1500-2500, and >2500 g), weight for gestational age (small for gestational age, appropriate for gestational age, and large for gestational age), and 1 minute Apgar score (≤7 and >7).